Skip to main content

Table 3 Resolution of treatment-related side effects on follow-up (n = 14)

From: Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

typical side effects CTC grade end of treatment (N = 14) 6 weeks post completion of treatment, N = 14 4-5 months post completion of treatment, N = 14
mucositis I 2 (14.3%) 5 (35.7%) 3 (21.4%)
  II 8 (57.1%%) 2 (14.3%)  
  III 4 (28.6%) 0  
dermatitis I 2 (14.3%) 6 (42.9%)  
  II 6 (42.9%) 0  
  III 2 (14.3%) 0  
acneiforme skin rash I 5 (35.7%) 1 (7.1%)  
  II 9 (64.3%) 0  
  III 1 (7.1%) 0  
dysphagia I 5 (35.7%) 4 (28.6%)  
  II 7 (50%) 9 (64.3%) 3 (21.4%)
  III 1 (7.1%) 1 (7.1%) 1 (7.1%)
xerostomia I 8 (57.1%) 9 (64.3%) 10 (71.4%)
  II 5 (35.7%) 2 (14.3%) 1 (7.1%)